Company attributes
Other attributes
BerGenBio is clinical-stage biopharma developing first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
BerGenBio has raised a total of $150.7M in funding over 8 rounds. Their latest funding was raised on May 5, 2020 from a Post-IPO Equity round.
BerGenBio is registered under the ticker OSE:BGBIO.
Their stock opened with NOK25.00 in its Apr 6, 2017 IPO.
BerGenBio is funded by 4 investors. Investinor and Meteva AS are the most recent investors.
BerGenBio uses 21 technology products and services including HTML5, Google Analytics, and jQuery, according to G2 Stack.
BerGenBio is actively using 20 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and Google Font API.
